Based on the LeMaitre Vascular Inc stock forecast from 4 analysts, the average analyst target price for LeMaitre Vascular Inc is USD 99.67 over the next 12 months. LeMaitre Vascular Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of LeMaitre Vascular Inc is Slightly Bullish , which is based on 9 positive signals and 7 negative signals. At the last closing, LeMaitre Vascular Inc’s stock price was USD 82.82. LeMaitre Vascular Inc’s stock price has changed by +3.81% over the past week, +0.63% over the past month and +28.11% over the last year.
No recent analyst target price found for LeMaitre Vascular Inc
No recent average analyst rating found for LeMaitre Vascular Inc
Company Overview LeMaitre Vascular Inc
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It also provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular and porcine patches; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts. Read Less
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used i...Read More
Frequently Asked Questions About LeMaitre Vascular Inc (LMAT) Stock
Based on ratings from 4 analysts LeMaitre Vascular Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 2 buy, sell and 3 hold ratings.
LMAT stock's dividend yield is 0.93%.
Our analysis grades LMAT stock's dividend yield at F. This means that LMAT stock's dividend yield is above 25% of the stocks in the Medical Instruments & Supplies sector in the NSD exchange.
Based on this LMAT may be a poor dividend stock for its sector.
Based on targets from 4 analysts, the average taret price for LMAT is USD 99.67 over the next 12 months. The maximum analyst target price is USD 110 while the minimum anlayst target price is USD 93.
LMAT stock's Price/Earning ratio is 44.41.
Our analysis grades LMAT stock's Price / Earning ratio at F. This means that LMAT stock's Price/Earning ratio is above 67% of the stocks in the Medical Instruments & Supplies sector in the NSD exchange.
Based on this LMAT may be a overvalued for its sector.
The last closing price of LMAT's stock was USD 82.82.
The most recent market capitalization for LMAT is USD 1.93B.
Based on targets from 4 analysts, the average taret price for LMAT is projected at USD 99.67 over the next 12 months.
This means that LMAT's stock price may go up by +20.34% over the next 12 months.
We can't find any ETFs which contains LeMaitre Vascular Inc's stock.
As per our most recent records LeMaitre Vascular Inc has 651 Employees.
LeMaitre Vascular Inc's registered address is 63 Second Avenue, Burlington, MA, United States, 01803.
You can get more information about it from LeMaitre Vascular Inc's website at https://www.lemaitre.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High dividend returns
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Dividend Growth
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About LeMaitre Vascular Inc (LMAT) Stock
Based on ratings from 4 analysts LeMaitre Vascular Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 2 buy, sell and 3 hold ratings.
LMAT stock's dividend yield is 0.93%.
Our analysis grades LMAT stock's dividend yield at F. This means that LMAT stock's dividend yield is above 25% of the stocks in the Medical Instruments & Supplies sector in the NSD exchange.
Based on this LMAT may be a poor dividend stock for its sector.
Based on targets from 4 analysts, the average taret price for LMAT is USD 99.67 over the next 12 months. The maximum analyst target price is USD 110 while the minimum anlayst target price is USD 93.
LMAT stock's Price/Earning ratio is 44.41.
Our analysis grades LMAT stock's Price / Earning ratio at F. This means that LMAT stock's Price/Earning ratio is above 67% of the stocks in the Medical Instruments & Supplies sector in the NSD exchange.
Based on this LMAT may be a overvalued for its sector.
The last closing price of LMAT's stock was USD 82.82.
The most recent market capitalization for LMAT is USD 1.93B.
Based on targets from 4 analysts, the average taret price for LMAT is projected at USD 99.67 over the next 12 months.
This means that LMAT's stock price may go up by +20.34% over the next 12 months.
We can't find any ETFs which contains LeMaitre Vascular Inc's stock.
As per our most recent records LeMaitre Vascular Inc has 651 Employees.
LeMaitre Vascular Inc's registered address is 63 Second Avenue, Burlington, MA, United States, 01803.
You can get more information about it from LeMaitre Vascular Inc's website at https://www.lemaitre.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for LMAT !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
